Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
Tài liệu tham khảo
Aegerter, 2022, Biology of lung macrophages in health and disease, Immunity, 55, 1564, 10.1016/j.immuni.2022.08.010
Westphalen, 2014, Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity, Nature, 506, 503, 10.1038/nature12902
Neupane, 2020, Patrolling alveolar macrophages conceal bacteria from the immune system to maintain homeostasis, Cell, 183, 110, 10.1016/j.cell.2020.08.020
Gschwend, 2021, Alveolar macrophages rely on GM-CSF from alveolar epithelial type 2 cells before and after birth, J. Exp. Med., 218, e20210745, 10.1084/jem.20210745
Guilliams, 2013, Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF, J. Exp. Med., 210, 1977, 10.1084/jem.20131199
Schneider, 2014, Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages, Nat. Immunol., 15, 1026, 10.1038/ni.3005
Suzuki, 2008, Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA, J. Exp. Med., 205, 2703, 10.1084/jem.20080990
Tazawa, 2019, Inhaled GM-CSF for pulmonary alveolar proteinosis, N. Engl. J. Med., 381, 923, 10.1056/NEJMoa1816216
Jakubzick, 2013, Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes, Immunity, 39, 599, 10.1016/j.immuni.2013.08.007
Byrne, 2020, Dynamics of human monocytes and airway macrophages during healthy aging and after transplant, J. Exp. Med., 217, e20191236, 10.1084/jem.20191236
Aegerter, 2020, Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection, Nat. Immunol., 21, 145, 10.1038/s41590-019-0568-x
Guilliams, 2021, Does tissue imprinting restrict macrophage plasticity?, Nat. Immunol., 22, 118, 10.1038/s41590-020-00849-2
Mould, 2017, Cell origin dictates programming of resident versus recruited macrophages during acute lung injury, Am. J. Respir. Cell Mol. Biol., 57, 294, 10.1165/rcmb.2017-0061OC
Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med., 382, 1708, 10.1056/NEJMoa2002032
Vabret, 2020, Immunology of COVID-19: current state of the science, Immunity, 52, 910, 10.1016/j.immuni.2020.05.002
Gu, 2021, Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation, Nat. Rev. Cardiol., 18, 194, 10.1038/s41569-020-00469-1
Dorward, 2021, Tissue-specific immunopathology in fatal COVID-19, Am. J. Respir. Crit. Care Med., 203, 192, 10.1164/rccm.202008-3265OC
Wauters, 2021, Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages, Cell Res., 31, 272, 10.1038/s41422-020-00455-9
Bost, 2021, Deciphering the state of immune silence in fatal COVID-19 patients, Nat. Commun., 12, 1428, 10.1038/s41467-021-21702-6
Liao, 2020, Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19, Nat. Med., 26, 842, 10.1038/s41591-020-0901-9
Zhao, 2021, Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients, Sci. Immunol., 6, eabf6692, 10.1126/sciimmunol.abf6692
Vanderbeke, 2021, Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity, Nat. Commun., 12, 4117, 10.1038/s41467-021-24360-w
Chua, 2020, COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis, Nat. Biotechnol., 38, 970, 10.1038/s41587-020-0602-4
Sefik, 2022, A humanized mouse model of chronic COVID-19, Nat. Biotechnol., 40, 906, 10.1038/s41587-021-01155-4
Merad, 2020, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat. Rev. Immunol., 20, 355, 10.1038/s41577-020-0331-4
Stephenson, 2021, Single-cell multi-omics analysis of the immune response in COVID-19, Nat. Med., 27, 904, 10.1038/s41591-021-01329-2
Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med., 8, 420, 10.1016/S2213-2600(20)30076-X
Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0
Lucas, 2020, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature, 584, 463, 10.1038/s41586-020-2588-y
Rösler, 2016, Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia-a new therapeutic strategy?, Mol. Cell. Pediatr., 3, 29, 10.1186/s40348-016-0055-5
Unkel, 2012, Alveolar epithelial cells orchestrate DC function in murine viral pneumonia, J. Clin. Invest., 122, 3652, 10.1172/JCI62139
Greter, 2012, GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells, Immunity, 36, 1031, 10.1016/j.immuni.2012.03.027
Thwaites, 2021, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci. Immunol., 6, 6, 10.1126/sciimmunol.abg9873
Ingelfinger, 2021, Master regulator of the T cell-phagocyte interface during inflammation, Semin. Immunol., 54, 101518, 10.1016/j.smim.2021.101518
Sterner, 2019, GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts, Blood, 133, 697, 10.1182/blood-2018-10-881722
Lang, 2020, GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches, Nat. Rev. Immunol., 20, 507, 10.1038/s41577-020-0357-7
Mehta, 2020, Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities, Lancet Respir. Med., 8, 822, 10.1016/S2213-2600(20)30267-8
Bosteels, 2020, Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): a structured summary of a study protocol for a randomised controlled trial, Trials, 21, 491, 10.1186/s13063-020-04451-7
Li, 2022, ScRNA-seq expression of IFI27 and APOC2 identifies four alveolar macrophage superclusters in healthy BALF, Life Sci. Alliance, 5, e202201458, 10.26508/lsa.202201458
Gibbings, 2017, Three unique interstitial macrophages in the murine lung at steady state, Am. J. Respir. Cell Mol. Biol., 57, 66, 10.1165/rcmb.2016-0361OC
Street, 2018, Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics, BMC Genom., 19, 477, 10.1186/s12864-018-4772-0
Grant, 2021, Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia, Nature, 590, 635, 10.1038/s41586-020-03148-w
van de Laar, 2016, Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages, Immunity, 44, 755, 10.1016/j.immuni.2016.02.017
Gautier, 2012, Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages, Nat. Immunol., 13, 1118, 10.1038/ni.2419
Ma, 2021, Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection, Sci. Immunol., 6, 6, 10.1126/sciimmunol.abh2259
Morrissey, 2021, A specific low-density neutrophil population correlates with hypercoagulation and disease severity in hospitalized COVID-19 patients, JCI Insight, 6, 148435, 10.1172/jci.insight.148435
Giamarellos-Bourboulis, 2020, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe, 27, 992, 10.1016/j.chom.2020.04.009
Lim, 2021, Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality, Ann. Intensive Care, 11, 50, 10.1186/s13613-021-00836-2
d'Alessandro, 2020, Serum KL-6 concentrations as a novel biomarker of severe COVID-19, J. Med. Virol., 92, 2216, 10.1002/jmv.26087
Leisman, 2022, Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19, Am. J. Respir. Crit. Care Med., 205, 507, 10.1164/rccm.202106-1514OC
Myhre, 2020, Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19, Circulation, 142, 2128, 10.1161/CIRCULATIONAHA.120.050360
Greter, 2012, GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells, Immunity, 6, 1031, 10.1016/j.immuni.2012.03.027
Grifoni, 2021, SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19, Cell Host Microbe, 29, 1076, 10.1016/j.chom.2021.05.010
Weiskopf, 2020, Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome, Sci. Immunol., 5, eabd2071, 10.1126/sciimmunol.abd2071
Bost, 2020, Host-viral infection maps reveal signatures of severe COVID-19 patients, Cell, 181, 1475, 10.1016/j.cell.2020.05.006
Liao, 2011, Down-regulation of granulocyte-macrophage colony-stimulating factor by 3C-like proteinase in transfected A549 human lung carcinoma cells, BMC Immunol., 12, 16, 10.1186/1471-2172-12-16
De Alessandris, 2019, Neutrophil GM-CSF receptor dynamics in acute lung injury, J. Leukoc. Biol., 105, 1183, 10.1002/JLB.3MA0918-347R
Sturrock, 2010, Mechanisms of suppression of alveolar epithelial cell GM-CSF expression in the setting of hyperoxic stress, Am. J. Physiol. Lung Cell Mol. Physiol., 298, L446, 10.1152/ajplung.00161.2009
Herold, 2014, Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome, Am. J. Respir. Crit. Care Med., 189, 609, 10.1164/rccm.201311-2041LE
Overgaard, 2015, The relative balance of GM-CSF and TGF-beta1 regulates lung epithelial barrier function, Am. J. Physiol. Lung Cell Mol. Physiol., 308, L1212, 10.1152/ajplung.00042.2014
Sturrock, 2012, GM-CSF provides autocrine protection for murine alveolar epithelial cells from oxidant-induced mitochondrial injury, Am. J. Physiol. Lung Cell Mol. Physiol., 302, L343, 10.1152/ajplung.00276.2011
Huang, 2011, GM-CSF in the lung protects against lethal influenza infection, Am. J. Respir. Crit. Care Med., 184, 259, 10.1164/rccm.201012-2036OC
Subramaniam, 2014, Protecting against post-influenza bacterial pneumonia by increasing phagocyte recruitment and ROS production, J. Infect. Dis., 209, 1827, 10.1093/infdis/jit830
Zhou, 2020, Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses, Immunity, 53, 864, 10.1016/j.immuni.2020.07.026
Temesgen, 2022, Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial, Lancet Respir. Med., 10, 237, 10.1016/S2213-2600(21)00494-X
Fisher, 2022, Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial, Lancet Respir. Med., 10, 255, 10.1016/S2213-2600(21)00460-4
Cremer, 2021, Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial, Lancet. Rheumatol., 3, e410, 10.1016/S2665-9913(21)00070-9
Presneill, 2002, A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction, Am. J. Respir. Crit. Care Med., 166, 138, 10.1164/rccm.2009005
Paine, 2012, A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury, Crit. Care Med., 40, 90, 10.1097/CCM.0b013e31822d7bf0